HOXD13 and non-small cell lung carcinoma: Interestingly, Ohkuma et al. [38] suggested a potential involvement of sPD-1 in primary resistance to anti-PD-1 ICIs in patients with various solid tumors, including NSCLC, and that early changes of this marker during the course of treatment may help identify patients least likely to respond.